Vaizensell Recruits Key Talent for Business Development and GMP to Accelerate Commercialization

Vaizensell, a company specializing in new drug development, announced on January 28 that it has recruited new executives to oversee business development and GMP (Good Manufacturing Practice) operations in order to accelerate the commercialization of 'VT-EBV-N', which has produced positive Phase 2 top-line data, as well as the pipeline being co-developed with Therabest.

Vaizensell appointed Executive Director Sunyoung Kim as Head of Business Development at the Innovation Strategy Division, and Executive Director Suhee Jeon as Head of the GMP Division. This recruitment is a strategic move to bring in talent responsible for strengthening the company’s core pipeline commercialization and GMP capabilities.

Executive Director Sunyoung Kim graduated from Ewha Womans University with a degree in pharmacy and obtained both her master's and doctoral degrees from the same university. She then worked as a postdoctoral researcher at Stanford University School of Medicine and gained experience in new drug development research at a U.S. biotech company. Subsequently, she served as a manager for the SPARK Translational Research Program at Stanford School of Medicine and as Executive Director at the Global Business Division of Ildong Pharmaceutical, where she led the establishment and operation of Ildong USA. She has been responsible for licensing out (L/O) and reviewing and promoting partnerships for global pipelines, and is recognized as a talent who combines research expertise with global business acumen gained through an MBA.

With the recruitment of Executive Director Kim, Vaizensell plans to focus on the commercialization of 'VT-EBV-N', which recently secured positive Phase 2 top-line data, targeting the Asian market and pursuing licensing out opportunities. In particular, the company aims to achieve results by positioning China, with its large patient base, as a strategic hub, while also making every effort to enhance the global value of its subsequent pipelines, such as 'VC-302' for glioblastoma and 'VC-420' for hepatocellular carcinoma.

Executive Director Suhee Jeon, who has joined as Head of the GMP Division, is an expert in the GMP field. She graduated from Seoul National University, earned a master's degree in biotechnology from Inha University, and a doctorate in life sciences from Incheon National University. She has accumulated about 27 years of experience in GMP operations and production facility management at companies such as Celltrion, Janssen Vaccines, and EuBiologics, and recently obtained an MBA from Seoul School of Integrated Sciences & Technologies (aSSIST).

Executive Director Jeon will be responsible for advancing the production process systems and strengthening the quality systems at Vaizensell's GMP Center. She will also lead efforts to enhance the company's capabilities in advanced regenerative medicine and CDMO business, which are expected to expand with the implementation of the revised Advanced Regenerative Medicine Act.

A Vaizensell representative stated, "This recruitment of new executives is a strategic move to further strengthen the company’s cell therapy technology and commercial momentum," adding, "In a highly competitive environment for talent acquisition, we will concentrate our capabilities to achieve visible results such as global licensing agreements and revenue generation."